Fact CheckerSign in

NCT06641336Recruiting

Perceptions of RehAtt Mixed Reality System

Perceptions of Using RehAtt Mixed Reality System in Stroke Motor Rehabilitation

Source: ClinicalTrials.gov · Last updated 15 Jun 2026

Brief summary (registry, in English)

The study aims to explore the patients' perspective on usability and feasibility of the RehAtt™ mixed-reality system during upper limb, gait and balance function rehabilitation.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
10 (estimated)
First submitted
11 Oct 2024
Start date
11 Oct 2024
Primary completion date
31 Oct 2026
Lead sponsor
University Rehabilitation Institute, Republic of Slovenia
Diseases
Stroke
NCT number
NCT06641336

What you commit to

  • Study type: Interventional
  • Planned participants: 10
  • From 11 Oct 2024 to the primary completion date, 31 Oct 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • severe cognitive impairment,
  • known presence of an epileptic seizure in the last year,
  • other orthopaedic and neurological diseases affecting sensory or motor functions,
  • severe visual impairment,

Other

  • aphasia,
  • inability to sit independently,
  • severe depression.

Who the study is looking for

  • first ischaemic or hemorrhagic stroke,
  • one-sided hemiparesis,
  • adequate cognitive abilities.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University Rehabilitation Institute, Republic of Slovenia
Coordinator of this site? Confirm its status		LjubljanaSloveniaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.